Focus:
The UK Department of Health and Social Care has announced a £25m contract for express freight service to deliver medicines and medical products after the country exits the European Union...
AstraZeneca and Merck have announced that Lynparza (olaparib), the primary product in their ongoing oncology collaboration, has performed better than the standard of care as a first line maintenance treatment...
Eli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis.
Biopharmaceutical firm CureVac has signed a collaborative research agreement with US-based Yale University to discover new therapeutic candidates for the treatment of pulmonary diseases.
AstraZeneca has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Calquence (acalabrutinib) to treat chronic lymphocytic leukaemia (CLL).
Boehringer Ingelheim has collaborated with The University of Texas MD Anderson Cancer Center to create a joint Virtual Research and Development Center focused on oncology research.
Researchers from Statens Serum Institut (SSI), Denmark, and Imperial College London have published promising results from the first clinical trial of a vaccine for Chlamydia, the most common sexually transmitted...
Irish biopharmaceutical company Jazz Pharmaceuticals has acquired US-based biotechnology firm Cavion for a total potential sum of $312.5m.
The US Senate Finance Committee Chairman Chuck Grassley has asked Novartis to provide information on data manipulation issues related to the company’s subsidiary AveXis’ spinal muscular atrophy (SMA) drug Zolgensma.
Biotechnology company Sonnet BioTherapeutics has agreed to acquire all outstanding shares of Relief Therapeutics under a binding share exchange agreement with Relief Therapeutics Holding.
